Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2021-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2021
2021-05-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release with financial results for the quarter ended March 31, 2020. It also includes a corporate slide presentation under Item 7.01 "Regulation FD Disclosure." The document itself is a filing announcing these materials rather than containing the full financial results or detailed financial statements. The length is 4906 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces financial results and presentations but does not contain the full financial data should be classified as a Regulatory Filing (RNS).
2021-05-13 English
SC 13D/A
Major Shareholding Notification
2021-05-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-05-04 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-05-04 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.